For generations, Alzheimer's disease has resisted every attempt at cure, in part because researchers have focused on the brain's chemistry while the immune system quietly failed in the background. Now, forty patients across three countries have received an experimental therapy — IBC-Ab002 — designed not to clear amyloid plaques but to restore the brain's own aging defenses, a distinction rooted in decades of work by Israeli neuroscientist Michal Schwartz. The Phase 1 results, published in Nature Medicine, found the treatment safe at every dose and biologically active as designed, offering a sm